Turkish Journal of Medical Sciences
Volume 41

Number 6

Article 7

1-1-2011

ICSI outcome in severely oligoasthenozoospermic patients and its
relationship to prewash progressive sperm motility*
NİLGÜN TURHAN
ASLIHAN PEKEL
AYLİN AYRIM
ÖMER BAYRAK

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
TURHAN, NİLGÜN; PEKEL, ASLIHAN; AYRIM, AYLİN; and BAYRAK, ÖMER (2011) "ICSI outcome in severely
oligoasthenozoospermic patients and its relationship to prewash progressive sperm motility*," Turkish
Journal of Medical Sciences: Vol. 41: No. 6, Article 7. https://doi.org/10.3906/sag-1005-835
Available at: https://journals.tubitak.gov.tr/medical/vol41/iss6/7

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Original Article

N. TURHAN, A. PEKEL, A. AYRIM, Ö. BAYRAK
Turk J Med Sci
2011; 41 (6): 995-999
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-1005-835

ICSI outcome in severely oligoasthenozoospermic patients and
its relationship to prewash progressive sperm motility*
Nilgün TURHAN, Aslıhan PEKEL, Aylin AYRIM, Ömer BAYRAK

Aim: To investigate the association between prewash progressive sperm motility and pregnancy rate in cases of severely
oligoasthenozoospermic patients in intracytoplasmic sperm injection (ICSI) cycles.
Materials and methods: The study included 80 infertile couples who were treated by ICSI due to severe
oligoasthenozoospermia (<106). Results were obtained by retrospective analysis of data that are regularly entered into
SPSS in our In Vitro Fertilization Unit. Female patients older than 35 years were excluded. The patients were divided
into 2 groups according to prewash progressive sperm motility. Group I had progressive sperm motility below 10% (n
= 40), and group II had progressive sperm motility equal to or greater than 10% (n = 40). The main outcome measure
was the clinical pregnancy rate.
Results: The patient characteristics were similar in both groups. There were no significant differences between the 2
groups in terms of total number of oocytes retrieved, number of mature oocytes, fertilization rate, or the number of
transferred embryos. A total of 38 (47.5%) clinical pregnancies were obtained in 80 ICSI treatment cycles. The clinical
pregnancy rate was significantly higher in group II (62.5% [25/40] than in group I (32.5% [13/40]), with P = 0.014.
Conclusion: Severe sperm motility impairment results in human infertility, which can be overcome by ICSI. The data
from this study demonstrated that severe progressive motility defects in cases of severe oligoasthenozoospermia do not
prevent fertilization or normal embryo production in ICSI cycles; however, the rate of ICSI success may be influenced
by progressive sperm motility. Our results show that oligoasthenozoospermic patients with progressive sperm motility
above 10% have better clinical pregnancy results.
Key words: Intracytoplasmic sperm injection, oligoasthenozoospermia, pregnancy

Yıkama öncesi progresif sperm motilitesinin ciddi oligoastenozoospermisi olan
hastalarda İCSİ sonuçları üzerine etkisi
Amaç: İCSİ yapılan ciddi oligoastenozoospermik hastalarda yıkama öncesi progresif sperm motilitesi ile gebelik oranı
arasındaki ilişkiyi araştırmak.
Yöntem ve gereç: Ciddi oligoastenozoospermi (<106) nedeni ile İCSİ ile tedavi edilen 80 infertil çift çalışmaya dahil
edildi. Sonuçlar IVF ünitemizde düzenli olarak SPSS istatistik programına kaydedilen verilerin retrospektif analizi ile
değerlendirildi. 35 yaşından büyük kadın hastalar çalışmaya dahil edilmedi. Hastalar yıkama öncesi progresif sperm
motilitesine göre iki gruba bölündü. Grup 1, progresif sperm motilitesi <% 10 (n = 40), grup 2 progresif sperm motilitesi
>% 10 (n = 40). Sonuç klinik gebelik oranı ile değerlendirildi.
Bulgular: Hasta karakteristikleri her iki grupta benzerdi. Her iki grup arasında, toplanan toplam yumurta sayısı, matür
oosit sayısı, fertilizasyon oranı ve transfer edilen embriyoların sayısı ile ilgili olarak önemi farklılıklar yoktu. 80 İCSİ
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tedavi siklusunda toplam 38 (% 47,5) klinik gebelik elde edildi. Klinik gebelik oranı grup 2’de (% 62,5), grup 1’e (% 32,5)
göre belirgin olarak daha yüksekti, P = 0.014.
Sonuç: Ciddi sperm motilite bozuklukları İCSİ ile tedavi edilebilen insan infertilitesi ile sonuçlanmaktadır. Bu
çalışmadan elde edilen veriler ciddi oligoastenozoospermisi olan olgulardaki progresif sperm motilite defektlerinin
İCSİ sikluslarında normal fertilizasyon ve normal embryo gelişimini engellemediğini göstermektedir, fakat, İCSİ başarı
oranı progresif sperm motilitesinden etkilenebilir. Bizim sonuçlarımız % 10’un üzerinde progresif sperm motilitesi olan
oligoastenozoospermik hastaların klinik gebelik sonuçlarının daha iyi olduğunu göstermiştir.
Anahtar sözcükler: İCSİ, oligoastenozoospermi, gebelik

Introduction
The technique of in vitro fertilization (IVF) was
successfully applied for the first time in 1978 to
bypass complete occlusion of the fallopian tubes (1).
Since then, the indications for IVF have expanded
internationally to include other infertility conditions
such as male infertility, endometriosis-associated
infertility, immunological infertility, and unexplained
infertility, or as the last option for couples with
infertility who have tried and failed to conceive using
standard therapies (2,3).
The management of male infertility totally changed
after the introduction of intracytoplasmic sperm
injection (ICSI). This technique was rapidly integrated
into the routine clinical practice of fertility clinics
offering assisted reproductive technology (ART)
throughout the world as a potential treatment for
severe male infertility (oligoasthenoteratospermia),
and high rates of fertilization and pregnancy have
been reported (4,5). During recent years, ICSI
has become the most frequently used method for
fertilization, and, in 2004, ICSI was used in nearly
60% of all reported ART cycles in Australia and New
Zealand, Europe, and the USA (6-8). In a recent
publication of trends in the use of ICSI in the USA,
it was shown that from 1995 to 2004, the proportion
of cycles in which ICSI was used increased from 11%
to 57.5% (9). Several studies have indicated that there
has been a global decrease in sperm concentration
during the past 5 to 6 decades (10-14), with wide
regional differences (12,15). A real decline in semen
quality and a higher proportion of subfertile men
could be a contributing factor to the rise in the use
of ICSI. It could also be speculated that an increase
in subtle changes in semen quality, which may not
always be recorded as male infertility, has occurred.
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The total number of motile sperm after sperm
preparation has been shown to predict the outcome
after IVF (16) and a count of 500,000 has been
suggested as a cut-off value for IVF (17), although
others recommend a number of >106 progressive
motile sperm (16). However, a metaanalysis of
sibling oocytes studied in patients with moderate
oligoasthenoteratozoospermia (OAT) revealed that
the odds of fertilization after ICSI were 3.9-fold
greater than with IVF. The number needed to treat
(NNT) in order to prevent 1 complete fertilization
failure after IVF could be 3, indicating that 3 ICSI
procedures would have to be performed instead of
conventional IVF in couples with moderate OAT in
order to prevent 1 complete fertilization failure (18).
There are fewer unexpected fertilization failures in
the ICSI group, but if embryos are obtained, ICSI
embryos generate a similar percentage of pregnancies
as do IVF embryos (19). It has been suggested that
ICSI should be the treatment of choice in all assisted
reproduction cycles.
Our aim was to investigate the association
between progressive sperm motility and pregnancy
rate in cases of severely oligoasthenozoospermic
patients treated with ICSI cycles in couples where the
woman’s age was 35 or younger.
Materials and methods
The study included 80 infertile couples
who were treated with ICSI due to severe
oligoasthenozoospermia (<106) at the Fatih University
School of Medicine Reproductive Endocrinology and
IVF Unit between August 2005 and July 2009. Results
were obtained by retrospective analysis of data that
are regularly entered into SPSS.

N. TURHAN, A. PEKEL, A. AYRIM, Ö. BAYRAK

The patients had a comprehensive history
taken followed by physical examination, including
gynecologic examination. Patients were excluded
from this analysis if the female’s age was older than 35.
Hormone levels, including day 3 follicle-stimulating
hormone (FSH) and estradiol (E2), were evaluated
in all women, and transvaginal ultrasonography was
performed to evaluate endometrial thickness.
The patients were divided into 2 groups according
to prewash progressive sperm motility. Group I had
progressive sperm motility below 10% (n = 40), and
group II had progressive sperm motility equal to or
greater than 10% (n = 40).
Ovarian stimulation was performed using a long
protocol of the standard technique of gonadotropinreleasing hormone agonist downregulation and
controlled stimulation with a recombinant FSH.
Cycles were monitored by ultrasonography and
serial monitoring of E2 levels. Once the follicular
sizes exceeded 17 mm, ovum pick-up (OPU) was
performed under general anesthesia. On the OPU
day, sperm retrieval was also performed and ICSI
was performed on mature eggs. Fertilization was
confirmed 24 h later and embryo transfer was
performed on day 3 after OPU. The main outcome
measure was the clinical pregnancy rate.
Results
The clinical characteristics of women in group I
and group II are presented in Table 1. None of the
evaluated parameters demonstrated significant
differences. There were no significant differences

noted between the 2 groups in terms of the total
number of oocytes retrieved, number of mature
oocytes, number of transferred embryos, or
fertilization rate (Table 2). A total of 38 (47.5%)
clinical pregnancies were obtained in 80 ICSI
treatment cycles. The clinical pregnancy rate was
significantly higher in group II (62.5% [25/40]) than
in group I (32.5% [13/40]), with P = 0.014.
Conclusion
Severe sperm motility impairment results in
human infertility, which can be overcome by ICSI. The
report of the first pregnancy with the intracytoplasmic
injection of sperm and the high fertilization rate
reported by Van Steirteghem et al. brought new
hope for couples with severe male-factor infertility
(5). The approach to patients with various sperm
defects like oligoasthenoteratospermia has changed
significantly with the introduction of sperm retrieval
techniques and assisted reproduction, especially with
ICSI. In addition to improving pregnancy rates using
sperm from ejaculated semen, ICSI has opened new
possibilities for achieving pregnancy with sperm
retrieved from the epididymis or testes, approaches
which have been performed for more than 10 years.
Satisfactory results have been achieved in various
studies using these techniques (4).
ICSI results were shown to be the same
with various sperm defects such as severe
oligospermia,
oligoasthenoteratospermia,
and
asthenoteratospermia (20,21). Nevertheless, it is well
known that the outcomes of ICSI are much better

Table 1. Clinical characteristics of the patients.
Group I
(n = 40)

Group II
(n = 40)

P-value

Age (female)

28.97 ± 3.66

28.82 ± 4.00

>0.05

Age (male)

33.05 ± 5.32

32.55 ± 4.66

>0.05

Duration of infertility (years)

5.21 ± 3.55

4.68 ± 2.86

>0.05

Day 3 FSH (mIU/ mL)

7.25 ± 2.19

7.14 ± 2.51

>0.05

40.11 ± 21.15

33.27 ± 28.33

>0.05

9.32 ± 1.85

9.62 ± 1.88

>0.05

Day 3 E2 (pg/mL)
Endometrial thickness
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Table 2. Outcome measures of the patients.
Group I
(n = 40)

Group II
(n = 40)

P-value

Number of oocytes

12.00 ± 6.21

10.68 ± 4.26

>0.05

Number of mature oocytes

7.83 ± 4.04

8.55 ± 3.76

>0.05

Fertilization rate (%)

63.60 ± 27.30

69.20 ± 21.59

>0.05

Number of embryos
transferred

2.34 ± 0.77

2.21 ± 0.69

>0.05

32.5% (13/40)

62.5% (25/40)

0.014

Clinical pregnancy (%)

when motile sperm can be selected (22,23), even
though each spermatozoon is immobilized before
injection. In the present study, asthenozoospermia
is defined as a low proportion of progressive motile
spermatozoa (+4 and +3) of less than 10% in a fresh
semen sample. Different conditions may impair
sperm motility, but the etiology of asthenozoospermia
often remains unknown. Motile spermatozoa should
be selected for ICSI not because of their movements
but with a view to their vitality. Progressive motility
may be an indicator of adequate metabolic activity
of the spermatozoon. This may explain why when
viable but immotile spermatozoa were used for ICSI,
the resulting embryos were of diminished quality and
had poor developmental potential (24).

The data from this study demonstrate that severe
progressive motility defects in cases of severely
oligoasthenozoospermic patients do not prevent
fertilization or normal embryo production when
ICSI is used. However, the rate of ICSI success may be
influenced by progressive sperm motility. Our results
show that oligoasthenozoospermic patients with
progressive sperm motility above 10% give better
clinical pregnancy results.
We conclude that progressive sperm motility is
an important and powerful factor in determining
the chance of pregnancy in oligoasthenozoospermic
patients.
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